Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bionime Corporation (4737:TWSE), powered by AI.
Bionime Corporation is currently trading at $54.90. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Bionime Corporation on Alpha Lenz.
View Bionime Corporation's valuation metrics on Alpha Lenz.
“Bionime Corporation's ROE is -9.9%. Explore profitability and growth together.”
Ask for details →Bionime Corporation is a company specializing in the design and production of medical diagnostic devices, primarily focusing on blood glucose monitoring systems. Renowned for its innovation in the healthcare sector, Bionime offers a range of products designed to provide accurate, user-friendly results for both personal and professional healthcare settings. The company's core product lines include glucose meters, test strips, and related accessories that cater to the growing global demand for diabetes management solutions. Bionime integrates cutting-edge technology with ergonomic design, ensuring ease of use and reliable data for users. Its products are extensively used across hospitals, clinics, and by individual patients, which underscores their critical role in chronic disease management. Established in 2003 and headquartered in Taichung, Taiwan, Bionime has rapidly expanded its international presence by adhering to stringent regulatory standards, thus gaining widespread trust in various markets. With a focus on continuous improvement and customer care, Bionime Corporation significantly contributes to the medical device landscape, offering essential tools that support impactful health outcomes.
“Bionime Corporation's ROE is -9.9%. Explore profitability and growth together.”
Ask for details →Bionime Corporation (ticker: 4737) is a company listed on TWSE in the Healthcare sector (Medical Instruments & Supplies).
The current price is 54.9 with a P/E ratio of -x and P/B of -x.
ROE is -9.95% and operating margin is -11.05%. Annual revenue is $1.8B.